CAMP4 Therapeutics (CAMP) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 30.7% versus a loss of 33.4%. CAMP4 Therapeutics is the larger company by market cap ($237.8 million vs $217.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | RCKT |
|---|---|---|
| Share price | $3.79 | $1.95 |
| Market cap | $237.84M | $217.74M |
| 1-day change | -5.25% | -7.58% |
| YTD return | -38.17% | -44.44% |
| 1-year return | +30.69% | -33.45% |
| 5-year return | — | -91.76% |
| EPS (TTM) | $-2.11 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.50M | $0 |
| Revenue growth (YoY) | +436.50% | — |
| Net income (latest FY) | $-80.40M | $-223.12M |
| Operating margin | -1502.43% | — |
| Net margin | -2298.54% | — |
| 52-week high | $7.75 | $5.45 |
| 52-week low | $2.90 | $1.94 |
| Distance from 52-week high | -51.10% | -64.22% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +169.66% | +326.15% |
| Average volume | 238.88K | 1.90M |
| Shares outstanding | 62.75M | 111.66M |
| Employees | 48 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed RCKT by 64.1 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
CAMP vs RCKT FAQ
Which is bigger, CAMP4 Therapeutics or Rocket Pharmaceuticals?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $237.84M compared with $217.74M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, CAMP or RCKT?
CAMP returned +30.69% over the past 12 months, compared with -33.45% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.